Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMRN

IMMURON (IMRN) Stock Price, News & Analysis

IMMURON logo

About IMMURON Stock (NASDAQ:IMRN)

Advanced Chart

Key Stats

Today's Range
$1.85
$2.13
50-Day Range
$4.80
$5.61
52-Week Range
$1.50
$2.87
Volume
12,391 shs
Average Volume
15,300 shs
Market Capitalization
$11.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

IMMURON Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

IMRN MarketRank™: 

IMMURON scored higher than 29% of companies evaluated by MarketBeat, and ranked 800th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IMMURON has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IMMURON has received no research coverage in the past 90 days.

  • Read more about IMMURON's stock forecast and price target.
  • Earnings Growth

    Earnings for IMMURON are expected to decrease in the coming year, from ($0.02) to ($0.03) per share.

  • Price to Book Value per Share Ratio

    IMMURON has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.49% of the float of IMMURON has been sold short.
  • Short Interest Ratio / Days to Cover

    IMMURON has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IMMURON has recently increased by 9.80%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IMMURON does not currently pay a dividend.

  • Dividend Growth

    IMMURON does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.49% of the float of IMMURON has been sold short.
  • Short Interest Ratio / Days to Cover

    IMMURON has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IMMURON has recently increased by 9.80%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for IMMURON this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for IMRN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added IMMURON to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IMMURON insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.01% of the stock of IMMURON is held by insiders.

  • Percentage Held by Institutions

    Only 0.12% of the stock of IMMURON is held by institutions.

  • Read more about IMMURON's insider trading history.
Receive IMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMURON and its competitors with MarketBeat's FREE daily newsletter.

IMRN Stock News Headlines

[ATTENTION] This Crypto Rocket Is About Launch…
Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to two crypto experts, that moment is here. Their Crypto Code Workshop shows how to get positioned before altcoins take off, ride the wave, and lock in gains — with a free $10 Bitcoin bonus just for attending.
Immuron Letter to Shareholders: Projects Update
See More Headlines

IMRN Stock Analysis - Frequently Asked Questions

IMMURON (IMRN) raised $6 million in an initial public offering (IPO) on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that IMMURON investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), AbbVie (ABBV), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX).

Company Calendar

Today
7/16/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED-BIOMED/GENE
Sub-Industry
N/A
Current Symbol
NASDAQ:IMRN
CIK
1660046
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+162.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.80
Quick Ratio
5.92

Sales & Book Value

Annual Sales
$3.21 million
Price / Sales
3.47
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.46 per share
Price / Book
1.30

Miscellaneous

Outstanding Shares
5,850,000
Free Float
5,439,000
Market Cap
$11.14 million
Optionable
Not Optionable
Beta
0.82
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:IMRN) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners